Clinical trials
NSCLC, Stage I clinical trials
Below are recruiting nsclc, stage i clinical trials, each written for real people, not researchers. We’re tracking 151 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06028412Enrolling by invitation
Lobectomy vs. Sublobar Resection for Small NSCLC
This trial compares two types of lung surgery for early-stage non-small cell lung cancer. You may qualify if you have a small tumor (2 cm or less) with specific features on a CT scan. The goal is to see which surgery offers better outcomes.
Xi'an, ShannxiAges 18–75 - NCT06810609RecruitingPhase 2
Immunochemotherapy, surgery, and durvalumab for stage III lung cancer
This trial tests a combination of immunotherapy, chemotherapy, and either surgery or radiation for people with stage IIIA or IIIB non-small cell lung cancer. The goal is to see if adding the drug durvalumab after standard treatment helps control the cancer better.
Freiburg im Breisgau, Baden-WurttembergAges 18–74 - NCT07122258Recruiting
Using the CAROL device to treat early stage lung cancer
This trial tests a new device called the CAROL that uses heat to destroy small lung tumors during surgery. It is for people with a specific type of early-stage lung cancer (stage 1, tumor 2 cm or smaller) that is located in the outer part of the lung and can be removed by surgery.
Melbourne, VictoriaAges 18 years+ - NCT06680050RecruitingPhase 2
Study of radiation plus two drugs for advanced lung cancer after prior treatment
This trial tests whether adding two drugs, durvalumab and ceralasertib, after radiotherapy can help patients with stage III non-small cell lung cancer whose cancer has come back in the chest or spread to a few other spots after previous treatment with durvalumab. It aims to improve outcomes by boosting the immune system's ability to fight the cancer.
BresciaAges 18 years+ - NCT07565987Recruiting
Stereotactic Radiation for Advanced Lung Cancer Without Chemotherapy
This trial tests whether a special type of focused radiation therapy can effectively treat advanced non-small cell lung cancer (the most common type) as an upfront treatment. It may help patients avoid or delay chemotherapy while controlling their cancer.
Jhajjar, HaryanaAges 18–75 - NCT07365319RecruitingPhase 2/Phase 3
New drug combo for stage 4 lung cancer
This trial tests a new drug called EIK1001 combined with standard immunotherapy (pembrolizumab) and chemotherapy for people with stage 4 non-small cell lung cancer who have not been treated before. The goal is to see if adding EIK1001 helps shrink tumors more than the current standard treatment.
Daphne, AlabamaAges 18 years+ - NCT06262321RecruitingPhase 2
Chest Radiation for Advanced Lung Cancer at High Risk of Symptoms
This study tests whether giving radiation to tumors in the chest soon after starting systemic therapy can help prevent symptoms like pain, trouble breathing, or bleeding. It is for people with advanced non-small cell lung cancer that does not have certain gene changes and has high-risk tumors in the chest.
Rochester, New YorkAges 18 years+ - NCT05668650RecruitingPhase 3
Study MB12 versus Keytruda for newly diagnosed stage IV lung cancer
This Phase 3 trial compares MB12 with Keytruda (both cancer medicines) for people with newly diagnosed stage IV non-squamous non-small-cell lung cancer. It looks at whether MB12 can work as well or better than Keytruda, and compares safety and immune responses.
Viedma, Río Negro ProvinceAges 18 years+ - NCT07632365RecruitingPhase 1/Phase 2
Immunotherapy plus chemoradiation for inoperable stage III lung cancer
This trial tests a new combination of immunotherapy and chemotherapy before and after standard chemoradiation for patients with stage III lung cancer that cannot be surgically removed. The goal is to see if this approach improves outcomes compared to chemoradiation alone.
Shanghai, XuhuiAges 18 years+ - NCT06088771RecruitingPhase 1/Phase 2
Study of dupilumab and cemiplimab before lung cancer surgery
This study tests two drugs, dupilumab and cemiplimab, given before surgery for early-stage lung cancer. The goal is to see if these immune-boosting medicines can shrink the tumor and improve outcomes.
New York, New YorkAges 18 years+ - NCT05011487RecruitingPhase 2
Before-surgery osimertinib plus chemotherapy for EGFR lung cancer
This study tests whether giving osimertinib together with chemotherapy before surgery can shrink and control EGFR-mutant, stage III lung cancer so it can be fully removed. If it works, it may improve the chances that the cancer does not come back after surgery.
Guangzhou, GuangdongAges 18–75 - NCT05940532RecruitingPhase 2
Sutimab plus chemotherapy for advanced lung cancer needing radiation
This trial tests a cancer-fighting antibody (sugemalimab) added to standard chemotherapy for stage III lung cancer that can’t be removed by surgery but may be treated with radiation. It aims to improve control of your cancer while checking safety and side effects.
ChangshaAges 18–75 - NCT06123754RecruitingPhase 3
Envafolimab plus chemo for stage III NSCLC before surgery
This trial tests a new immunotherapy (Envafolimab) combined with standard chemotherapy before and after surgery for stage III non-small cell lung cancer that can be removed. The goal is to see if adding Envafolimab helps shrink the tumor and improve outcomes compared to chemotherapy alone.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06598839Recruiting
Immune effects of thymosin alpha-1 for stage I lung cancer
This trial tests whether thymosin alpha-1, an immune-boosting medicine, can help people with stage I non-small cell lung cancer after surgery. The goal is to see if it improves the immune system's response and recovery.
Beijing, Beijing MunicipalityAges 18–75 - NCT06709859RecruitingPhase 2
Afatinib plus chemo for unresectable stage III lung cancer
This trial tests whether combining afatinib (a targeted pill for EGFR mutations) with chemotherapy can shrink advanced stage III non-small cell lung cancer (NSCLC) enough to make surgery possible. It is for people whose cancer has not been treated yet and has a specific EGFR mutation.
Jinan, ShangdongAges 18 years+ - NCT07131319RecruitingPhase 2/Phase 3
Combination therapy for advanced lung cancer
This trial tests a new treatment combining stereotactic radiation (SFRT), the immunotherapy tislelizumab, and platinum chemotherapy for people with stage III non-small cell lung cancer that can't be removed with surgery. It aims to see if this combination helps shrink or control the cancer better.
Nanchang, JiangxiAges 18–85 - NCT06924710Recruiting
Adaptive therapy for early stage lung cancer with no MRD detected
This study tests a new approach for people with early-stage non-small cell lung cancer (NSCLC) who have had their tumor completely removed. It uses regular blood tests (MRD monitoring) to watch for any cancer cells left behind, so treatment can be given only if needed.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05398094RecruitingPhase 2
Sotorasib for KRAS-mutant Stage III lung cancer without chemo-radiation
This Phase 2 study tests sotorasib (also called AMG510) in people with Stage III lung cancer that cannot be removed by surgery and that has a specific KRAS mutation (p.G12C). You may be able to join if you cannot safely receive chemo-radiotherapy at the same time, and the study checks whether sotorasib can help shrink or control the cancer.
Alicante, AlicanteAges 18 years+ - NCT07010419RecruitingPhase 3
Firmonertinib vs placebo for early-stage lung cancer with rare EGFR mutations
This trial tests if Firmonertinib, a targeted pill, can prevent lung cancer from returning after surgery in people with non-small cell lung cancer that has certain uncommon EGFR gene changes. If you have had complete tumor removal and have one of these specific mutations, this study may help you stay cancer-free longer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04631770Recruiting
Mediastinal node removal versus sparing nodes for early lung nodule
This trial compares two surgical approaches for people with a single small, noncancer-looking lung nodule (a GGN) that is diagnosed as very early lung cancer. It aims to see whether removing mediastinal lymph nodes—or leaving them alone—can lead to better outcomes with less harm.
Tianjin, Tianjin MunicipalityAges Any age - NCT05211895RecruitingPhase 3
Durvalumab plus domvanalimab after chemoradiation for stage 3 lung cancer
This trial studies whether adding durvalumab and domvanalimab after standard chemoradiation can keep unresectable stage 3 lung cancer from coming back or getting worse. It targets tumors with specific lab test results (including PD-L1 and gene markers).
Chandler, ArizonaAges 18 years+ - NCT07153445RecruitingPhase 2
Atezolizumab before and after surgery for stage III lung cancer
This trial tests whether the immunotherapy drug atezolizumab, given before and after surgery, can help treat stage III non-small cell lung cancer that has not spread to other parts of the body. It is for people who have not had any previous cancer treatment for this disease.
Alicante, AlicanteAges 18 years+ - NCT07131163Recruiting
Study of lung cancer patients who got chemo-immunotherapy before planned surgery but didn't have surgery
This study looks at patients with stage II or III non-small cell lung cancer who started chemotherapy plus immunotherapy before planned surgery but did not actually have surgery. It aims to understand why surgery was canceled and how patients did over time.
Ramat GanAges 18 years+ - NCT06221670RecruitingPhase 2
Toripalimab after surgery for high-risk early lung cancer
This trial tests whether giving a drug called Toripalimab after surgery can help prevent early-stage non-squamous non-small cell lung cancer from coming back. It is for people whose tumors have high-risk features and PD-L1 levels of at least 1%.
Tianjin, Tianjin MunicipalityAges 18 years+
Hear when a new NSCLC, Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nsclc, stage i?
- Yes. Clin2 currently lists 151 recruiting nsclc, stage i studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nsclc, stage i trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nsclc, stage i trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.